AstraZeneca taps Chinese academia to bolster CV pipeline
This article was originally published in Scrip
Executive Summary
AstraZeneca has entered into an alliance with a Chinese research institute with the aim of developing novel therapies for the treatment of cardiovascular diseases and ultimately bolstering its pipeline in the field.